Clinical observation of a patient with TMEM127 and EGLN1 gene variants, pheochromocytoma and pancreatic tumor-Reference-Cited by-同舟云学术

Clinical observation of a patient with TMEM127 and EGLN1 gene variants, pheochromocytoma and pancreatic tumor

Published:2021-05-12 Issue:7 Volume: Page:150-154
ISSN:2658-5790
Container-title:Meditsinskiy sovet = Medical Council
language:
Short-container-title:Medicinskij sovet

Author:

Yukina M. Yu.¹^ORCID,Mustafina V. R.¹^ORCID,Vasilyev E. V.¹^ORCID,Troshina E. A.¹^ORCID,Platonova N. M.¹^ORCID,Beltsevich D. G.¹^ORCID

Affiliation:

1. National Medical Research Center for Endocrinology

Abstract

Pheochromocytoma/paraganglioma is a neuroendocrine tumor of chromaffin and nonchromaffin cells of the autonomic nervous system, in most cases localized in the medullary layer of the adrenal gland. Its development is often associated with genetic predisposition. More than 30% of adult patients have genetically determined PCC/PG. In the last decade, many genes predisposing to the manifestation of PCC/PG have been found: RET, VHL, NF1, SDHB, SDHC, SDHD, SDHA, SDHAF2, TMEM127, MAH, KIF1BP, PHD2, EGLN1, FH, H-RAS, IDH, SLC25A11, MDH2. Mutation of the oncosuppressor genes TMEM127 and EGLN1, which regulate the level of factors induced by HIF hypoxia, is extremely rare in patients with PCC/PG, and has not been described at all in combination with pancreatic tumor. To date, data on the clinical manifestations of these gene mutations are limited. Accumulating clinical data on patients with identified genetic alterations is important for predicting the course of the disease, clarifying the malignant potential and stratifying the risk of developing comorbid pathology. We present the clinical case of a 62-year-old patient with PCC/PG and pancreatic tumor in whom a previously undescribed combination of TMEM127 c.99G > A (p.S33S) and EGLN1 c.515C > T (p.A172V) gene variants was found.

Publisher

Remedium, Ltd.

Subject

General Medicine

Reference12 articles.

1. Mercado-Asis L.B., Wolf K.I., Jochmanova I., Taieb D. Pheochromocytoma: a genetic and diagnostic update. Endocr Pract. 2018;24(1):78-90. doi: 10.4158/EP-2017-0057.

2. Richards S., Aziz N., Bale S., Bick D., Das S., Gastier-Foster J. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-423. doi: 10.1038/gim.2015.30.

3. Shabalina S.A., Spiridonov N.A., Kashina A. Sounds of silence: synonymous nucleotides as a key to biological regulation and complexity. Nucleic Acids Res. 2013;41(4):2073-2094. doi: 10.1093/nar/gks1205.

4. Amorim-Pires D., Peixoto J., Lima J. Hypoxia Pathway Mutations in Pheochromocytomas and Paragangliomas. Cytogenet Genome Res. 2016;150(3-4):227-241. doi: 10.1159/000457479.

5. Ladroue C., Carcenac R., Leporrier M., Gad S., Le Hello C., Galateau-Salle F. et al. PHD2 mutation and congenital erythrocytosis with paraganglioma. N Engl J Med. 2008;359(25):2685-2692. doi: 10.1056/NEJMoa0806277.